Evidence map›Paper›PMID 42519144›Full record

ArticleIDCases2026

First reported recovery and genomic characterization of a previously uncharacterized

Nobuhiro Asai, Yuriko Igarashi, Narimi Miyazaki, Arufumi Shiota, Yuka Yamagishi, Akiko Nakamura, Asami Osugi, Yuki Matsumoto, Shota Nakamura, Satsuki Murakami and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in IDCases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nobuhiro AsaiDepartment of Clinical Infectious Diseases, Aichi Medical University, Nagakute, Aichi, Japan.
Yuriko IgarashiThe Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan.
Narimi MiyazakiDepartment of Infection Prevention and Control, Aichi Medical University, Nagakute, Aichi, Japan.
Arufumi ShiotaDepartment of Infection Prevention and Control, Aichi Medical University, Nagakute, Aichi, Japan.
Yuka YamagishiDepartment of Clinical Infectious Diseases, Aichi Medical University, Nagakute, Aichi, Japan.
Akiko NakamuraDepartment of Infection Prevention and Control, Aichi Medical University, Nagakute, Aichi, Japan.
Asami OsugiThe Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan.
Yuki MatsumotoDepartment of Infection Metagenomics, Bioinformatics Center, Research Institute for Microbial Diseases, Osaka University, Japan.
Shota NakamuraDepartment of Infection Metagenomics, Bioinformatics Center, Research Institute for Microbial Diseases, Osaka University, Japan.
Satsuki MurakamiDepartment of Hematology, Aichi Medical University, Nagakute, Aichi, Japan.
Akiyoshi TakamiDepartment of Hematology, Aichi Medical University, Nagakute, Aichi, Japan.
Satoshi MitaraiThe Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan.
Hiroshige MikamoDepartment of Clinical Infectious Diseases, Aichi Medical University, Nagakute, Aichi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mycobacteremia is an uncommon opportunistic infection in immunocompromised hosts. We report the recovery of a previously uncharacterized Mycobacterium species from two independent blood culture sets obtained from an immunocompromised patient with persistent fever. She presented with persistent fever, and two independent blood culture sets yielded a

Indexed as

Average nucleotide identityImmunocompromised hostMycobacteremiaNovel Mycobacterium speciesWhole-genome sequencing

Identifiers

PMID42519144
PMCPMC13382135

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.